It has also been reported that the AR point mutations W741C, T877A, W741L, W741C/T877A, F876L, F876L/T877A, and L701H can switch Bicalutamide (Bic), a first generation anti-androgen, from an AR antagonist to a potent AR agonist leading to reactivation of AR signaling in PCa under therapy. Here, AR is linked to posterior cortical atrophy.